Cancer Second Opinions in China: MDT Reviews for Travelers (2026)

A cancer second opinion in China means asking a large oncology centre — ideally through a multidisciplinary team (MDT) review — to re-examine your diagnosis, staging and treatment plan. Done well, it is a records-first process: pathology, imaging and treatment summaries travel ahead of you, and the in-person visit takes days, not weeks. Done badly, it is an expensive trip to be told "we need your slides". This guide covers how to prepare, what Chinese oncology can realistically offer — including particle therapy and the Boao Lecheng drug-access channel — and how to keep your home oncologist in the loop. For treatment itself (not just an opinion), China is a specialist-only decision that should never be made from a website.

Why an MDT review is the right format

Modern cancer decisions cross specialty lines: whether to operate, irradiate, treat systemically, or sequence all three. China's national cancer control plan for 2023–2030 explicitly directs hospitals to "continue advancing the multidisciplinary diagnosis and treatment model", build disease-specific centres, and extend capacity with telemedicine^[1]. In practice, major tertiary oncology hospitals run scheduled MDT clinics where a surgeon, medical oncologist, radiation oncologist, pathologist and radiologist review a case together.

For an international patient, an MDT consult has two advantages over a single-professor appointment: you get one reconciled recommendation instead of serial, possibly conflicting ones, and the pathology and imaging re-reads — the parts most likely to change a plan — happen inside the same discussion. When contacting hospitals through our directory, ask specifically whether your case will go to an MDT discussion, what it costs, and which specialties will attend; see international departments explained for how these services are organised.

Send your records before you fly

The single highest-value thing you can do is assemble a complete, well-organised record package and ask for a preliminary (often remote) review before booking travel:

• Treatment summary from your oncologist: diagnosis, stage, treatments with dates and doses, response, current status.
• Pathology: the written report at minimum; ask the Chinese hospital whether they want stained slides or tissue blocks for re-reading — re-review of pathology is a core part of a serious second opinion.
• Imaging: original DICOM files (CD/USB or an upload link), not just printed reports or phone photos.
• Labs and genomics: recent bloods, tumour markers, and any molecular/genomic testing reports — these increasingly drive drug choices.
• Medication list and comorbidities, plus translations if the hospital requests them.

Our medical records and follow-up guide covers formats and certified translation; the bilingual inquiry letter gives you a structured bilingual way to ask a hospital exactly what they need and what a records review costs. Expect fees for remote review and for MDT time; no national price list exists, so get numbers in writing.

What Chinese oncology can offer — concretely

Scale and specialisation. National policy has pushed cancer care into networked, quality-controlled specialty centres, with single-disease quality control and national/regional cancer centres^[1]. Large centres see very high case volumes in China's common cancers — relevant if your tumour is one of them.

Particle therapy exists. The Shanghai Proton and Heavy Ion Center (SPHIC), affiliated with Fudan University Shanghai Cancer Center, describes itself as China's first — and the world's third — medical institution equipped with both proton and heavy-ion (carbon-ion) therapy, using a Siemens-engineered system, and states that suitability is confirmed through MDT review before treatment preparation begins^[2]. Additional particle-therapy projects are being built, including SPHIC's own second phase^[2]. Particle therapy is appropriate only for selected indications — an MDT must confirm yours before you plan anything around it.

Drug access is broader than it used to be. China's medical-insurance drug list added 744 new drugs between 2018 and 2023 through annual negotiation rounds^[4], and national policy calls for accelerating registration of foreign anticancer drugs and smoothing temporary-import channels for clinically urgent ones^[1]. For drugs approved abroad but not yet registered in the mainland, the Hainan Boao Lecheng International Medical Tourism Pilot Zone is the designated channel: under a special policy, licensed institutions there may use such imported drugs and devices, and real-world data collected in the zone can support later mainland approval — a pathway through which 21 products had been approved by China's drug regulator as of March 2025^[3]. Read our dedicated guide to Hainan Boao Lecheng before building hopes around a specific drug, and confirm availability of that exact drug directly with a Lecheng institution.

Realistic expectations

A second opinion is information, not a miracle:

• Most second opinions confirm the existing diagnosis; the valuable minority refine staging, pathology or options. Both outcomes are useful — neither is a promised breakthrough.
• Nobody can honestly quote success rates for you, and we do not publish success-rate claims. Be suspicious of anyone who guarantees outcomes.
• Advanced technology is not automatically better for your case: particle therapy, for example, has specific indications decided by MDT review^[2].
• Costs are real: records review, MDT fees, interpretation, travel, and — if treatment follows — a far larger commitment. See insurance for treatment abroad.

Who should not travel: anyone in urgent need of treatment where delay is dangerous, patients too unwell for long flights, and anyone mid-cycle in systemic therapy without their oncologist's explicit agreement. A remote records review may still be possible in all these cases — that is precisely its point.

Costs: ordinary clinic vs international department

Two price tiers: ordinary vs international/private. We found no verified public price range for this. In a public hospital's ordinary departments (普通门诊), basic services are billed at government-guided item prices that apply to every patient, foreigners included; 特需 (VIP) and international-department services are priced by the hospital at market rates and capped at a share of its services^[5]. Public hospitals sell bulk-procured (集采) drugs and devices at their purchase price, with no markup^[6]. As an illustration, China-Japan Friendship Hospital's published schedule lists a chief-physician consultation in its international department at ¥500, against ¥50 for an ordinary attending-physician appointment^[7]. You do not have to use the international department: with a passport you can register at the ordinary clinic and pay yourself (mainland insurance does not apply) — see your first hospital visit without a Chinese ID. The international department or a private hospital costs more but usually adds English-speaking staff, appointments and, often, direct billing with commercial insurers. Whichever route you choose, ask for a written quote.

Coordinating with your home oncologist

Tell your oncologist you are seeking a second opinion and ask for their summary — serious doctors are used to this, and their cooperation makes your record package dramatically better. After the review, bring back a written MDT report (ask for English or a certified translation) with the recommended plan, drug names in international (INN) form, and radiotherapy/surgery specifics. Decisions then happen at home, with your own team: continuity — who gives each cycle, who monitors toxicity, who handles complications — is the thing most likely to break when care crosses borders, and the plan is only as good as its hand-offs^[1]. If you do opt for treatment in China, treat it as a separate, specialist-led project with explicit answers on treatment duration, accommodation, follow-up and complication handling before you commit; see risks and complications.

Next steps

• Browse hospitals offering oncology consultations and the oncology specialty page.
• Use the bilingual inquiry letter to ask a hospital's international department about records review, MDT fees and timelines.
• If a specific not-yet-registered drug matters to you, start with the Boao Lecheng guide.
• Let the planner assemble a short consultation itinerary — records first, flights second.